AdultPediatricGeriatricDosage Forms & Strengths tablet 5mg tablet, extended-release 5mg 10mg 15mg syrup 5mg/5mL Overactive Bladder Relief of symptoms (eg, urge incontinence, frequency, urgency) in patients with uninhibited neurogenic or reflex neurogenic bladder Immediate-release: 5 mg PO twice/three times daily; not to exceed 5 mg PO four times daily Extended-release: 5-10 mg/day PO; may be increased by 5 mg/day at weekly intervals; not to exceed 30 mg/day Dose Modifications Renal Impairment Not studied; use caution Hepatic Impairment Not studied; use caution Dosage Forms & Strengths tablet 5mg tablet, extended-release 5mg 10mg 15mg syrup 5mg/5mL Detrusor Overactivity Bladder overactivity associated with a neurologic condition (eg, spina bifida) ≥5 years (immediate-release): 5 mg PO q12hr; may be increased to 5 mg PO q8hr ≥6 years (extended-release): 5 mg/day PO initially; may be increased by 5 mg/day at weekly intervals; not to exceed 20 mg/dayOveractive Bladder Relief of symptoms (eg, urge incontinence, frequency, urgency) in patients with uninhibited neurogenic or reflex neurogenic bladder Immediate-release: Initiate at lower dosage in frail elderly; 2.5 mg PO q8-12hr initially; may be increased to 5 mg q8-12hr if warranted Extended-release: 5-10 mg PO qDay; pharmacokinetics similar to adults in elderly up to age 78 yrInteraction CheckerEnter a drug name and oxybutyninNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (7)lonafarniboxybutynin will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.metoclopramide intranasaloxybutynin, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.olopatadine intranasaloxybutynin and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. potassium chloridepotassium chloride, oxybutynin. Other (see comment). Avoid or Use Alternate Drug. Comment: Patients using drugs with extensive anticholinergic effects should avoid concomitant use with solid oral dosage forms of potassium chloride. May use effervescent potassium preparations as alternatives. .pramlintidepramlintide, oxybutynin. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.ropeginterferon alfa 2bropeginterferon alfa 2b and oxybutynin both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.secretinoxybutynin decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.Monitor Closely (128)abobotulinumtoxinAabobotulinumtoxinA increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumoxybutynin and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.amantadineoxybutynin, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.amitriptylineoxybutynin and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapineoxybutynin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.aripiprazoleoxybutynin decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atracuriumatracurium and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineatropine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMatropine IV/IM and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.avapritiniboxybutynin will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.axitiniboxybutynin increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.belladonna alkaloidsbelladonna alkaloids and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumbelladonna and opium and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.benperidoloxybutynin decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.benperidol increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropinebenztropine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholbethanechol increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbacholcarbachol increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbamazepinecarbamazepine will decrease the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.oxybutynin will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor plasma levels when used concomitantlycenobamatecenobamate, oxybutynin. Either increases effects of the other by sedation. Use Caution/Monitor.cevimelinecevimeline increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazineoxybutynin decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cimetidinecimetidine will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cisatracuriumcisatracurium and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.clarithromycinclarithromycin will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clomipramineoxybutynin and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clozapineoxybutynin decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.clozapine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclizinecyclizine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.daridorexantoxybutynin and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramineoxybutynin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.dicyclominedicyclomine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.difelikefalindifelikefalin and oxybutynin both increase sedation. Use Caution/Monitor.diltiazemdiltiazem will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.diphenhydraminediphenhydramine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.donepezildonepezil increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, oxybutynin. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinoxybutynin and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinoxybutynin and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.droperidoloxybutynin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.droperidol increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.echothiophate iodideechothiophate iodide increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.erythromycin baseerythromycin base will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin stearateerythromycin stearate will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fesoterodinefesoterodine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.finerenoneoxybutynin will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.flavoxateflavoxate and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.flibanserinoxybutynin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.fluphenazineoxybutynin decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.fluphenazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.galantaminegalantamine increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.glycopyrrolateglycopyrrolate and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.haloperidoloxybutynin decreases effects of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.oxybutynin decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.haloperidol increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.henbanehenbane and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hyoscyaminehyoscyamine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneoxybutynin decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.iloperidone increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.imipramineoxybutynin and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ipratropiumipratropium and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isavuconazonium sulfateoxybutynin will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.itraconazoleitraconazole will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ivacaftoroxybutynin increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .ketoconazoleketoconazole will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lemborexantoxybutynin will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.letermovirletermovir increases levels of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.levoketoconazolelevoketoconazole will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.lofepramineoxybutynin and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.lomitapideoxybutynin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.loxapineoxybutynin decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledloxapine inhaled increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.oxybutynin decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.maprotilineoxybutynin and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.meclizinemeclizine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.methscopolaminemethscopolamine and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.metoclopramideoxybutynin decreases effects of metoclopramide by pharmacodynamic antagonism. Use Caution/Monitor. May antagonize prokinetic effects.midazolam intranasaloxybutynin will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.midazolam intranasal, oxybutynin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.nefazodonenefazodone will increase the level or effect of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.neostigmineneostigmine increases and oxybutynin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nitrofurantoinoxybutynin increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.nortriptylineoxybutynin and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.olanzapineoxybutynin decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.onabotulinumtoxinAonabotulinumtoxinA and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrineoxybutynin and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin topicaloxybutynin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin transdermaloxybutynin and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.paliperidoneoxybutynin decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral